AstraZeneca's Capivasertib NDA218197 Receives AP Status from FDA
The FDA has granted AstraZeneca's NDA218197 for Capivasertib an Approval Pending (AP) status.
Asset / Drug
Drug and asset intelligence for Capivasertib with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
AKT Inhibitor
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.